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Abstract 
PURPOSE 
In 2005, the European Association for Palliative Care (EAPC) made recommendations for 
prognostic markers in advanced cancer. Since then, prognostic tools have been developed, 
evolved and validated. The aim of this systematic review was to examine the progress in the 
development and validation of prognostic tools.   
METHODS 
Medline, Embase Classic + and Embase were searched. Eligible studies met the following 
criteria: patients with incurable cancer; >18 years; original studies; population n>100; 
published after 2003. Descriptive and quantitative statistical analyses were performed.   
RESULTS 
Forty-nine studies were eligible, assessing seven prognostic tools across different care 
settings, primary cancer types and statistically assessed survival prediction. The (PPS) 
Palliative Performance Scale was the most studied (n=21,082), composed of 6 parameters (6 
subjective), was externally validated and predicted survival. The Palliative Prognostic Score 
(PaP) composed of 6 parameters (4 subjective, 2 objective), the Palliative Prognostic Index 
(PPI) composed of 9 parameters (9 subjective), and the Glasgow Prognostic Score (GPS) 
composed of 2 parameters (2 objective), and were all externally validated in more than 2000 
patients with advanced cancer and predicted survival.  
CONCLUSION 
Various prognostic tools have been validated, but vary in their complexity, subjectivity and 
therefore clinical utility. The GPS would seem the most favourable as it uses only two 
parameters (both objective) and has prognostic value complementary to the gold standard 
measure, which is performance status.  Further studies comparing all proven prognostic 
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markers in a single cohort of patients with advanced cancer, are needed to determine the 
optimal prognostic tool.  
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Introduction 
Estimating prognosis is a fundamental component in the management of patients with 
advanced cancer for several reasons. Firstly, accurate estimation of prognosis can help inform 
whether anti-cancer treatment is likely to be beneficial.1,2 Secondly, it may relieve patient and 
carer anxiety associated with prognostic uncertainty.3 Thirdly it can help with end of life care 
planning, including place of care.  
 
However, in patients with advanced cancer the ceiling limit of the TNM classification system 
is often reached (i.e. M1) and as such is of limited value. As such, in the clinic, prognosis is 
based on various factors including stage of disease, performance status, previous clinical 
experience and knowledge of cancer trajectories. However the subjective nature of these may 
result in estimates of prognosis which are inaccurate, potentially misleading and may result in 
anti-cancer therapies being given inappropriately.2,4-6  
 
In an attempt to improve prognostic accuracy, in 2005the European Association of Palliative 
Care (EAPC) published recommendations on the use of prognostic markers in patients with 
advanced cancer.7 These recommendations were informed by eight studies examining 
different prognostic tools, which had been published in the preceding decade (1993-2003), 
and recommended a number of prognostic tools and their utilisation. These tools were: the 
Terminal Cancer Prognostic Score, the Palliative Performance Scale, the Palliative Prognostic 
Index and the Palliative Prognostic Score. 
  
Since these recommendations were made, a plethora of prognostic tools devised for use in 
patients with advanced cancer have been developed, however to date they have not been 
presented together and comparison made. To this end, the aim of this systematic review, was 
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to examine and compare prognostic tools in patients with advanced cancer and make 
recommendations for their use.  
 
Methods 
The following databases were searched: Medline (2003– 2015), Embase Classic + and 
Embase (2003 -2015). The search focussed on studies of prognostic tools in patients with 
advanced cancer regardless of the original primary tumour. The search terms are listed in 
Appendix 1. A hand search of key journals and relevant citations was carried out. The date of 
the last literature search was 30th April 2015.  
 
Eligibility Criteria 
Eligible studies met the following inclusion criteria: population with advanced cancer 
(defined as an incurable cancer); original studies; study population n >100 and age > 18 
years; quantitative clinical and/or biomarkers were examined; a multivariate statistical model 
was described; the tool had been examined and validated in two or more independent data 
sets; published in English; published after 2003 (end date of original literature search); and 
full paper was available.7 The primary outcome measurement examined was survival 
prediction (likelihood of death) based on the use of the prognostic tool in the specific patient 
population. Studies were excluded if: a univariate survival analysis was described only; the 
tool was designed for use in one specific population with one specific cancer type (e.g. only 
patients with specific stage of lung cancer) or qualitative indices were used exclusively to 
predict survival. 
 
Data extraction and analysis 
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The initial database search was undertaken and duplicates removed. Two authors (CS and 
KM) independently screened each study for eligibility based on the abstract and finally each 
full text article. From this, the necessary data for descriptive and quantitative analyses were 
extracted by CS and TS, independently. These included the descriptors of the patient 
population, length of survival and information regarding survival predictions. The analysis of 
each study was performed using standard quality assessment criteria which were then 
summarised for statistical analysis and comparison where possible.8 Studies are presented 
according to the prognostic tool described. Where studies examined both populations with 
cancer and non-cancer, only those populations with cancer were included in the analysis.  
 
Results 
The literature search process is shown in Figure 1. Following abstract review, 179 articles 
were reviewed in full and this resulted in 49 studies fulfilling the eligibility criteria.  
 
From the 49 eligible studies, seven different prognostic tools were identified. A summary of 
these is detailed in Table 1. The tools identified were the PaP (Palliative Prognostic Score - 8 
studies), D-PaP (Delirium-PaP - 2 studies), BCI (B12/CRP Index -1 study), PiPS (Prognosis 
in Palliative Care Study- 1 study), PPI (Palliative Prognostic Index -8 studies), PPS 
(Palliative Performance Scale - 18 studies) and the GPS (Glasgow Prognostic Score -10 
studies).  
 
A detailed description of these seven prognostic tools is given in Appendices 2 and 3. These 
tools used a combination of clinical and/or biomarker parameters. The most common clinical 
parameters used were performance status, anorexia and dyspnoea. The most common 
biomarkers were C-reactive protein (CRP), white cell count, lymphocyte count and albumin. 
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The number of parameters used ranged from two (GPS, BCI) to 17 (PiPS B), and the mean 
number was seven. The largest single population studied for each of the prognostic tools is 
summarised in Table 2. Details of all studies included in this review are summarised in 
Supplementary Table 1.  
 
To date, there have been eight studies (combined total n=2694) examining the PaP in patients 
with advanced cancer. Patient cohorts were unselected but included patients with a variety of 
cancer diagnoses including cancer of the head and neck, lung, skin, breast, gastrointestinal 
tract, genitourinary tract, prostate, gynaecological, neuroendocrine and haematological tissue.  
The studies were from groups in Australia (1 study), Italy (2 studies), Brazil (1 study), Japan 
(1 study), Canada (2 studies) and the USA (1 study), thereby providing external validation of 
the tool. Two studies, (n=910) examined the D-Pap in patients with advanced cancer.9,10 This 
included patients with cancers of the head and neck, lung, breast, gastrointestinal tract, 
genitourinary tract. Both the PaP and D-PaP predict survival in patients with advanced 
cancer. The D-PaP tool has not been as extensively validated compared with the PaP, 
however both perform similarly when compared with each other. 9  
 
To date, one study comprising 329 patients examined the BCI in patients with advanced 
cancer.11 The patient population included those with a diagnosis of cancer of the head and 
neck, lung, breast, gastrointestinal tract, genitourinary tract, prostate, gynaecological, 
neuroendocrine and haematological tissue. This study confirmed that an elevated BCI 
predicts poor survival.   
 
One study (n=1018) has examined the PiPS.12 The patients included those with diagnoses of 
gastrointestinal, lung, unknown primary, breast, urological, gynaecological, central nervous 
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system, haematological and head and neck cancers. This study reported that the area under 
the curve (AUC) varied between 0.79 (PiPS A) and 0.86 (PiPS B), and suggested that PiPS is 
at least equal to and may be better than the clinician’s predicted survival. 
   
Eight studies (n= 5929) have examined the prognostic value of the PPI.9,13-20 The patients 
included those with cancer of the head and neck, lung, breast, gastrointestinal tract, 
genitourinary tract, prostate, gynaecological and haematological tissue. The studies were 
based in Japan (3 studies), Italy (1 study), Taiwan (2 studies), USA (1 study) and Canada (1 
study). Recently studies have examined a change in PPI scores, and this approach to 
researching the PPI appears more consistent, accurate and clinically useful.   
 
Eighteen studies (n=21,082) have examined the PPS. The patients included those with 
diagnoses of cancer of the head and neck, lung, breast, gastrointestinal tract, genitourinary 
tract, prostate, gynaecological, neuroendocrine and haematological tissue.  The studies were 
based in the USA (6 studies), Spain (1 study), Canada (8 studies), Italy (1 study), Singapore 
(1 study) and South Korea (1 study), thereby providing external validation of the tool. Due to 
the numerous subgroups within the tool, earlier reports had stated it was not highly 
discriminating in the intermediate scores.7 Studies taking place after 2005 tackled this issue 
and focussed on the significance of a 10% decrement in PPS score or poorer PPS scores. A 
strong ordering effect across the different PPS categories was demonstrated, with highly 
accurate scores for a PPS of 40% or less. Patients with PPS categories greater than 50% had 
lower hazard ratios than patients with lower PPS scores.  
 
Ten studies (n=5163) have examined the GPS. The patients included those with diagnoses of 
cancer of the head and neck, lung, skin, breast, gastrointestinal tract, genitourinary tract, 
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prostate, gynaecological, neuroendocrine and haematological tissue. Eight studies were from 
groups based in the UK, one study was from Japan and one study examined data from an 
international bio bank of patients, providing external validation of this tool.  
 
A descriptive comparison of the individual clinical and biomarkers parameters included in the 
each of the prognostic tools is shown in Table 3. The number of markers ranges from 2 (GPS) 
to 17 (PiPSB).  The (PPS) is composed of 6 parameters (6 subjective), the Palliative 
Prognostic Score (PaP) composed of 6 parameters (4 subjective, 2 objective) the Palliative 
Prognostic Index (PPI) composed of 9 parameters (9 subjective), and the Glasgow Prognostic 
Score (GPS) composed of 2 parameters (2 objective). 
  
To date, there have been limited studies on the direct comparison of the prognostic value of 
the above tools.  One study compared the performance of the PaP to the D-PaP, PPS, and PPI 
and concluded that the PaP showed superior accuracy and reproducibility.9 The PaP was also 
directly compared with the PPS and PPI tools in separate studies.20,21 Tarumi et al. concluded 
that the PPS and the PaP performed similarly in survival prediction,21 whereas Kim et al. 
concluded that the PaP performed better.20  
 
Finally, direct comparison has been carried out between the GPS and ECOG performance 
status,22 and between the GPS and the PPI23 and reported that the GPS had prognostic value 
independent of ECOG-PS22 and PPI22,23. 
 
Discussion  
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Since the European Association for Palliative Care recommendations for prognostic tools 
were published in 2005 there have been a number of prognostic tools developed, evolved, and 
validated.7  The PPS has been studied in the greatest number of patients, externally validated 
and consistently predicts survival in patients with advanced cancer. Other prognostic tools of 
note, that have been validated and consistently predict survival are the PaP, the PPI, and the 
GPS. In addition, the latter (based on the combination of C-reactive protein and albumin), has 
been extensively validated since the original review. 
 
Most of the prognostic tools (PPS, PaP and the PPI) depend largely on the assessment of 
functional status as a core component. Therefore, their use in routine practice has been sparse 
compared to Karnofsky Performance Score or the simplified Eastern Cooperative Oncology 
Group Performance Score.24,25 In addition the relatively complex scoring systems of these 
prognostic tools may have prejudiced their routine use; whilst the similarities but clear 
differences in these is confusing and makes comparison challenging. Therefore, it would be 
important to rationalise these subjective assessments into a simpler scheme with as advocated 
by Harding and co-workers.26   
 
From the present review it is also clear that many of the tools such as PaP, PPI, PPS and even 
performance status are predominantly subjective and it could be argued that where possible, 
these should be made more objective. For example, one such way would be to examine if 
skeletal muscle mass is related to functional status, and whether it can be a surrogate marker 
of physical function. This would seem plausible as skeletal muscle indices are increasingly 
recognised to have prognostic value.27  
 
Although various prognostic tools have been validated they vary in their complexity, 
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subjectivity and therefore their clinical utility. The GPS would seem the most favourable as it 
uses only two parameters (both objective) and has prognostic value complementary to ECOG 
performance status, most commonly used assessment of patient physical function, in the 
oncology of advanced disease.  Further studies comparing all externally validated prognostic 
tools in a single cohort of patients with advanced cancer, are needed to determine the optimal 
prognostic tools. 
 
The search strategy in the present review was comprehensive and included the main medical 
databases and a detailed search strategy (appendix 1). However, there were three notable 
studies not included in the review.  Feliu and coworkers reported the development and 
validation of a prognostic nomogram for terminally ill patients with cancer in almost 900 
patients.28 However, it is of interest that the nomogram included the components ECOG-ps, 
LDH, lymphocyte count and albumin concentrations that have been used in other externally 
validated prognostic scores such as PaP that have been examined in the present review.  The 
second study by Kim and coworkers reported the external validation of PiPS-A and PiPS-B in 
202 terminally ill patients with cancer.29 Finally, our search was limited to 30th April 2015. 
This excluded a large external validation study (n = 2,426) of the modified PiPS-A and -B 
prognostic tools reported by Baba and coworkers in May 2015.30 Nevertheless present review 
is therefore a step towards the viewpoint of Harding and coworkers that ‘it would be 
important to rationalise these subjective assessments into a simpler scheme with “judicious 
selection and refinement of existing tools’ (The PRISMA Symposium 1: outcome tool use. 
Disharmony in European outcomes research for palliative and advanced disease care: too 
many tools in practice).31 
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Limitations 
It is clear that with the exception of the GPS and contrary to the REMARK guidelines, HR 
and 95% CI have been reported inconsistently in the prognostic tools developed for use in 
patients with advanced cancer.  This precluded meaningful meta-analysis in the present 
systematic review. Therefore, future research should directly compare these validated 
prognostic tools within all advanced cancer types using similar statistical approaches, in 
keeping with the REMARK guidelines.32  
 
The present systematic review updated a previous review published a decade ago.   The 
majority of the prognostic tools examined had less than five independent reports of their 
prognostic value and therefore a meta-analysis of the validated prognostic tools was not 
meaningful and a formal estimate of bias was not carried out. However, the data from each 
paper was presented in detail (supplementary Table 1) enabling the reader to draw 
conclusions as to their quality and the likelihood of bias using standard criteria. As a result 
the present systematic review is largely descriptive giving an update in the progress of 
prognostic tools in the field. 
 
Several key aspects of prognostic tools remain elusive and the present manuscript was unable 
to address these due to paucity of primary data. To illustrate, it is not clear if certain tools 
have greater utility in specific tumour types and/or at certain points in the cancer journey. 
Further, the potential role of these clinical tools in clinical practice is unclear as their 
usefulness in treatment stratification or place of care planning is unknown; both of these are 
unlikely to be addressed unless such tools are incorporated into routine clinical practice. 
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It is also clear that another challenge is to implement the right tool at the right point in the 
patient’s cancer journey. This is important as this can affect different aspects of care e.g. 
whether to treat with anti-cancer therapy, preferred place of death etc. To date the application 
of the right tool, at the right time remains elusive and is likely to require a combination of 
mixed methodologies to achieve this.  
 
Conclusion 
Prognosis remains a central tenet of care in cancer, and validated tools applied correctly may 
serve to improve patient care.  Since the previous systematic review and recommendations, 
many prognostic tools that have been examined are not integrated into routine clinical care. It 
could be argued that the multitude of tools available may have actually confused clinicians as 
to the optimal tool for use. Further, as performance status remains at the forefront of clinical 
decision making regarding prognosis, tools which build on this would seem preferable e.g. 
the GPS and ECOG-PS. To provide some clarity as to the optimal prognostic tool, studies are 
needed which compare all independent prognostic markers, in a single population. Such 
studies are eagerly awaited.  
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Figure 1. Flow chart of the review process 
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Table 1 - Summary of Prognostic Tools  
 
Tool Number of variables Cancer types 
(mixed/single) 
Number of studies***  
Clinical* 
(subjective)  
Biomarkers**  
(objective) 
PaP 4 2 Mixed and single 8 
D-PaP 5 2 Mixed only 2 
BCI 0 2 Mixed only 1 
PiPS A 
PiPS B 
13 
9 
0 
9 
Mixed  1 
PPI 5 0 Mixed only 8 
PPS 7 0 Mixed only 18 
GPS 0 2 Mixed and single 10 
 
*Clinical refers to signs or symptoms which are of prognostic significance 
**Biomarkers refers to serum biomarkers of prognostic significance  
***studies eligible for inclusion 
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Table 2 – Summary of Prognostic Tools –Largest Population Studied per Tool. 
Tool Authors Cancer  N Survival Outcome  Survival*  HR** Summary  P Value* 
PaP Tarumi et al21 Various 777 Continuous 35d  - Multivariate Cox regression model on overall survival: 
Including age, gender, diagnosis, initial PPS, initial PaP, MMSE score, and 
presence/absence of delirium on initial consultation. 
Log rank test: PaP Group A vs. group B vs. group C 
 
 
 
<0.001 
D-PaP 
 
Maltoni et al9 Various 549 Categorical  
(21d and 30d) 
22d - AUC 0.73 (95%CI 0.71-0.74) <0.0001 
BCI 
 
Kelly et al11 Various 329 Categorical (90d) 42d  
 
- Log rank test: 
BCI Group 1 vs. group 2 vs. group 3 
< 0.001. 
(group 1vs. 
group 2 
P = 0.091) 
PiPS Gwilliam et 
al12 
Various 1018 Continuous < 1 – 14w - AUC= 0.79-0.86 - 
PPI Kao et al 33 Various 2392 Continuous 5w 0.63 Multivariate Cox Regression: 
Adjusting for age, gender, primary cancer origin, referring medical department, and 
the interval between the hospital admission and referral dates 
< 0.001 
PPS Casarett et 
al34 
 
Various 7391 Categorical  
(7d) 
- - Multiple logistic regression: 
Probability of dying between PPS groups. 
< 0.001 
GPS Laird et al22 Various 2456 Categorical 
(3m) 
3.2m 1.51-2.27 Multivariate Cox proportional hazards model on overall survival: 
Test sample: 
Including age, cognitive function, dyspnea, appetite loss, quality of life, physical 
function, role function, fatigue, BMI, performance status and mGPS. 
HR 1.62–2.05 
Validation sample: 
Including quality of life, physical function, emotional function, pain, BMI, 
performance status and mGPS. 
HR 1.51–2.27 
Log rank test: 
Comparing levels of mGPS 
< 0.001 
 
 
 
 
 
< 0.01 
 
 
 
< 0.001 
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Supplementary Table 1 – Prognostic Tools 
Tool Authors Cancer  N Survival Outcome  Survival*  Summary  HR** P Value* 
PaP 
 
Glare et al35 Various 100 Categorical  
(4w) 
12w Log rank (test for trend): 
Probability of surviving 1 month: Group A vs. Group B vs. Group C 
-   
<0.0001 
Tassinari et 
al36 
Various 173 Continuous 26w Multivariate Cox regression model on overall survival:  
Including age, tumour type, number of metastatic sites, performance 
status, ESAS, PaP score. 
-   
 
0.022  
Naylor et al37 Various 250 Categorical  
(30d) 
95d Log rank test:PaP Group A vs. Group B vs. Group C - <0.0001 
Hyodo et al38 Various 208 Continuous 27d Cox proportional hazards: 
PaP Group B vs. Group A  
PaP Group B vs. Group C  
 
0.536 (0.36-0.779) 
3.72 (2.59-5.35) 
 
0.002  
<0.001 
Tarumi et al21 Various 777 Continuous 35d  Multivariate Cox regression model on overall survival: 
Including age, gender, diagnosis, initial PPS, initial PaP, MMSE score, 
and presence/absence of delirium on initial consultation. 
Log rank test: PaP Group A vs. group B vs. group C 
-  
 
 
<0.001 
Maltoni et al9 Various 549 Categorical  
(21d and 30d) 
22d Log rank test 
PaP Group A vs. group B vs. group C 
-   
< 0.001 
Kim et al20 Various 415 Categorical  
(4w) 
- A score of >10 was the optimal cut-off for predicting survival at 4 weeks - - 
Hui et al39 Various 222 Continuous 106d Cox proportional hazards regression analysis with backward 
selection: Incorporating age, sex, PaP, PPI, serum albumin, fat-free 
mass, unadjusted phase angle, handgrip strength, maximal inspiratory 
pressure, and standardized phase angle.PaP 
 
Log rank test:PPI group A vs. group B vs. group C 
1.07(1.02-1-13) 0.008 
 
 
 
 
< 0.001 
D-PaP 
 
Maltoni et al9 Various 549 Categorical  
(21d and 30d) 
22d D-PaP Group A versus Group B vs Group C - <0.001 
Scarpi at al10 Various 361 Categorical (30d) 4w “Validation by calibration” and K statistic 
 
1.6 (1.22-1.99) <0.001 
BCI 
 
Kelly et al11 Various 329 Categorical (90d) 42d  
 
Log rank test: 
BCI Group 1 vs. group 2 vs. group 3 
-  
< 0.001 
PiPS Gwilliam et 
al12 
Various 1018 Continuous < 1 – 14w Logistic Regression 
AUC=  0.79-0.86  
- - 
PPI Stone et al15  Various 194 Continuous Group1: 
68d 
Cox proportional hazards:  
The Hazard Ratio associated with a one unit increase in PPI score  
 
1.36 (1.29-1.43) 
  
< 0.001 
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Group2: 
21d 
Group3:5d 
 
Survival of less than three weeks was predicted with a PPV of 86% and 
negative predictive value NPV of 76%. 
Maltoni et al9 Various 549 Categorical  
(21d and 30d) 
22d PPI Group A versus Group B vs Group C - <0.001 
Cheng et al18 Various 623 Categorical  
(21d) 
- Cox proportional hazards: 
Group C vs. Group A:  
Group C vs. Group B:  
 
 
0.19 (0.10-0.24) 
0.54 (0.43-0.69)  
 
<0.001 
<0.001 
Kim et al20 Various 415 Categorical 
(4w) 
- Optimal scores for predicting 4wk survival over 4.5 - - 
Arai et al19 Various 374 Categorical 
(3w) 
- Multivariate Cox proportional hazards model on predicting death 
within 3 weeks: 
Including gender, age, BMI, BT, SBP, diastolic blood pressure, PR, 
initial PPI, and ∆ PPI. 
9.0 (4.1-20.0) to  
14.4 (5.7-36.2) 
 
< 0.01 
Kao et al 33 Various 2392 Continuous 5w Multivariate Cox Regression: 
Adjusting for age, gender, primary cancer origin, referring medical 
department, and the interval between the hospital admission and referral 
dates 
0.63 < 0.001 
Hui et al39 Various 222 Continuous 15w Log rank test: PPI group A vs. group B vs. group C 
Cox proportional hazards regression analysis with backward 
selection: Incorporating age, sex, PaP, PPI, serum albumin, fat-free 
mass, unadjusted phase angle, handgrip strength, maximal inspiratory 
pressure, and standardized phase angle. 
- 
- 
0.03  
- 
Miura et al40 Various 1160 Categorical  
(3w, 6w) 
<8w Cox regression analysis: 
Adjusted for primary cancer site, age, and gender. 
PPI=4-6 
PPI≥6 
 
 
1.11 (0.89-1.38) 
1.56 (1.27-1.92) 
 
 
0.376 
<0.001 
PPS Head et al41 Various 261 Continuous 29d Cox Proportional Hazards model on overall survival: 
Independent variables included PPS score category, comorbidity status, 
diagnosis, age, gender, race, and marital status. 
0.18(0.092-0.34) to 
0.43 (0.28-0.66) 
<0.05 
Harrold et al42  Various 214 Categorical 
(7d, 30d, 90d, 
180d) 
- Univariate Cox proportional hazards modeling: 
The area under the receiver operating characteristic (ROC) curve:  
To measure predictive accuracy in cancer pts. and non-cancer patients. 
0.96 <0.001 
Sanchez et 
al43 
 
Various 250 Continuous 32d Cox regression analysis on overall survival: PPS<50 
Adjusted for anorexia; compromised oral intake; agitation; delirium; 
apathetic mental state; confused or in coma; coherent language; 
2.21 (1.30-3.76) to 
8.33 (4.51-15.38) 
< 0.05 
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orientation in time, place, and person; hallucinations and/or illusions; 
heart rate; respiratory rate; PPS. 
Lau et al44 
 
Various 647 Continuous 10d Log rank test on overall survival: 
PPS groups 
- < 0.001 
Olajide et al45 
 
Various 157 Continuous 9d  Proportional hazards regression model on overall survival: 
Including PPS, dyspnea, pain, fatigue, and agitated delirium. 
10% decrease in PPS results in HR of 1.65 
1.65 (1.42-1.92) < 0.001 
Lau et al46 
 
Various 126 Continuous  Cox Regression 0.29 to -0.93 <0.001 
Lau et al47 Various 347 Continuous 37d Log rank test on overall survival: 
Initial PPS groups 
Increasing HR with increasing PPS group 
Multivariable Cox proportional hazards model on overall survival: 
Including gender, diagnosis, site and PPS. Increasing HR with 
increasing PPS group (PPS20%[0.40] to PPS 70%[0.039]) 
 
- 
 
 
 
0.039 (0.023-0.067) 
to 0.40 (0.25-0.64) 
< 0.001 
 
 
 
< 0.001 
< 0.001 
Weng et al48 
 
Various 492 Continuous 18d Log rank test on overall survival 
PPS group A vs. group B vs. group C 
 
Cox proportional hazards model on overall survival: 
Including age, gender, race/ethnicity, and PPS. 
- 
 
 
 
0.96 (0.95-0.07) 
< 0.05 
 
 
 
< 0.001 
Younis et al49 Various 180 Continuous 35d  Multivariate analysis with Cox proportional hazards model on 
overall survival: 
Including executed advanced directives, Medicare/Medicaid insurance, 
PPS and gender. 
1.73 (PPS<50) < 0.05 
Lau et al50 
 
Various 5097 Continuous 39d Log rank test on overall survival 
PPS groups compared 
 
Cox proportional hazards model on survival: 
Including age, gender, location, diagnosis category, and initial PPS. 
Increasing HR with PPS group (PPS 70 [0.056] – PPS 20 [0.54]).  
- 
 
 
 
0.056 (0.046-0.069) 
to 0.54 (0.49-0.61) 
< 0.001 
 
 
 
<0.001 
<0.001 
Selby et al51 
 
Various 1622 Continuous 26.5d Multivariate logistic regression analysis on overall survival: 
Including gender and PPS. 
 Group A and 
C: P < 0.0001 
Group B: 
P = 0.19 
Tarumi et al21 
 
Various 777 Continuous 43d Cox proportional hazards model on overall survival: 
Including age, gender, diagnosis, initial PPS, and survival curve time in 
 
0.021(0.099-0.46) to 
 
<0.001 
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days, initial PaP, MMSE score, and presence/ absence of delirium on 
initial consultation (PPS90% [0.21] PPS 40% [0.45])  
0.45 (0.31-0.66)  <0.001 
Casarett et 
al34 
 
Various 7391 Categorical  
(7d) 
- Multiple logistic regression: 
Probability of dying between PPS groups. 
- < 0.001 
Maltoni et al9 
 
Various 549 Categorical  
(21d and 30d) 
22d Log rank test: 
PPS Group A vs. group B vs. group C 
- < 0.0001 
Mei et al52 
 
Various 296 Categorical 
(90d) 
- Multivariate Cox proportional hazards model on overall survival: 
Including albumin, gender and baseline PPS scores (PPS 60-90%[0.31] 
PPS 20-30% [0.52]) 
0.31(0.16-0.58) to  
0.52 (0.36-0.76) 
<0.001 
<0.001 
Kim et al20 Various 415 Categorical 
(4w) 
- Optimal scores for predicting survival ≤ 30 - - 
Lee et al53 Various 606 Continuous - Change in score >30% significantly associated with survival 
 
2.66 (2.19-3.22) - 
Jang et al54 Various 1655 Continuous 133d Log-rank test for trend: 
Median survival between groups. 
- < 0.001 
GPS Sharma et al55 Ovary 154 Continuous 39.9m Multivariate Cox proportional hazard model on cancer specific 
survival: 
Including GPS, histological subtype, ascites, performance status, ALP, 
CRP and primary debulking surgery. 
1.68 (1.16-2.45) < 0.001 
Crumley et 
al56 
Gastro-
oesopha
geal 
258 Continuous - Multivariate Cox regression model on cancer specific survival: 
Including tumour site, stage, alkaline phosphatase, the GPS and 
treatment. 
1.51(1.22-1.86) < 0.001 
Glen et al57 
 
Pancreas 187 Categorical 
(12m) 
4.6m Multivariate Cox regression analysis on overall survival: 
Prognostic scores as covariates. 
1.72 (1.40-2.11) < 0.001 
Ramsey et al58 
 
Renal 119 Continuous 8m Multivariate Cox proportional-hazards model on cancer specific 
survival: 
Including lactate dehydrogenase, hemoglobin, calcium, white cell count, 
neutrophil count, albumin, and C-reactive protein. 
2.35 (1.51-3.67) < 0.001 
Forrest et al59 Lung  101 Continuous Active 
treatment: 
15.5m 
Palliative 
treatment: 
5.8m 
Multivariate Cox regression analysis on overall survival: 
Stratified for treatment 
 
2.32(1.52-3.54) < 0.001 
Partridge et 
al60 
Various 296 Categorical 
(2w, 4w) 
- Multivariable Cox regression model on overall survival: 
Including sex, primary cancer site, age, hemoglobin, and white cell 
2.71(1.25-5.88) 0.011 
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NB: Some studies compared several of these tools in one paper which explains the disparity in the total number of studies versus papers 
*Median **Hazard Ratio (Confidence Interval). Where cells are blank, data was unavailable. d=days, w=weeks, m=months.  
 
count (mGPS 2=2.71)  
Leung et al61 Lung  261 Continuous 8m Multivariate analysis on cancer specific survival: 1.67 (1.28-2.19)  0.0001 
Pinato et al62 Lung  171 Continuous 9.7m Multivariate Cox proportional hazard model on overall survival: 
Including gender, histologic subtype, PS, the European Organization for 
the Research and Treatment of Cancer Prognostic Score, WBC count, 
neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, CRP, 
albumin and mGPS. 
 
2.6 (1.6-4.2) <0.001 
Laird et al22 Various 2456 Categorical 
(3m) 
3.2m Multivariate Cox proportional hazards model on overall survival: 
Test sample: 
Including age, cognitive function, dyspnea, appetite loss, quality of life, 
physical function, role function, fatigue, BMI, performance status and 
mGPS. (mGPS 1[HR 1.62] mGPS 2 [2.05])  
Validation sample: 
Including quality of life, physical function, emotional function, pain, 
BMI, performance status and mGPS. (mGPS1 [1.58] mGPS [2.06) 
 
Log rank test: 
Comparing levels of mGPS 
 
 
1.62 (1.35-1.93) to 
2.05 (1.72-2.44) 
 
 
1.58 (1.25-2.01) to 
2.06 (1.62-2.63) 
 
 
<0.001 
<0.001 
 
 
<0.001 
<0.001 
 
 
< 0.001 
Miura et al40 Various 1160 Categorical  
(3w, 6w) 
- Multivariate Cox regression analysis on overall survival: 
Adjusted for primary cancer site, age, and gender. 
GPS=1  
GPS=2 
 
 
1.07 (0.78-1.49) 
1.36 ( 1.01-1.87) 
 
 
0.673 
0.046 
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Table 3 – Clinical and bio-markers per prognostic tool.  
*Performance status **Clinician Predicted Survival  
  Prognostic Tool 
  PaP D-Pap BCI PiPS-A PiPS-B PPI PPS mGPS GPS 
Cl
in
ic
al
 
M
ar
ke
r 
PS* x x  x x x x   
CPS** x x     x   
Anorexia/dec
reased oral 
intake 
x x  x x x x   
Dyspnoea x x  x  x    
Ambulation 
      x   
Delirium 
 x    x x   
Activity 
      x   
Evidence of 
disease 
      x   
Oedema 
     x    
Global 
Health 
   x x     
Breast 
Cancer 
   x      
Male genital 
organs 
   x x     
Distant 
Metastases 
   x x     
Bone 
metastases 
   x x     
Liver 
metastases 
   x      
Mental Test 
Score 
   x x     
Heart Rate 
   x x     
Dysphagia 
   x      
Weight loss – 
last month 
   x      
Fatigue 
    x     
B
io
m
ar
ke
rs
 
Lymphocyte 
count 
x x   x     
White cell 
count 
x x   x     
Neutrophil 
Count 
    x     
C-reactive 
protein 
  x  x   x x 
Albumin 
    x   x x 
Vitamin B12 
  x       
Platelets 
    x     
Urea 
    x     
Alanine 
Transaminase 
    x     
Alkaline 
Phosphatase 
    x     
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Database: Ovid MEDLINE(R) 1946 to Present with Daily Update, Embase Classic+Embase 
<1947 to 2015 Week 14> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     neoplasm.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1024167) 
2     cancer.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3421033) 
3     malignancy.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] 
(251965) 
4     tumo?r$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3908264) 
5     carcinoma.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] 
(1530087) 
6     1 or 2 or 3 or 4 or 5 (6273610) 
7     model.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3945411) 
8     tool.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (657880) 
9     7 or 8 (4498731) 
10     prognosis.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] 
(1151044) 
11     prediction.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] 
(498913) 
12     progno$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1332771) 
13     10 or 11 or 12 (1765582) 
14     terminal care.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] 
(48093) 
15     palliat$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (173421) 
16     hospice.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (26506) 
17     14 or 15 or 16 (217896) 
18     6 and 9 and 13 and 17 (1735) 
19     limit 18 to "all adult (19 plus years)" [Limit not valid in Embase; records were retained] 
(1626) 
20     limit 19 to english language (1499) 
21     limit 20 to humans (1370) 
22     remove duplicates from 21 (1088) 
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Table 4: The PaP 
Criterion for PaP  Score 
Dyspnoea Yes 
No 
1 
0 
Anorexia Yes 
No 
1.5 
0 
KPS ≥30 
10-20 
0 
2.5 
CPS (weeks) >12 
11-12 
7-10 
5-6 
3-4 
1-2 
0 
2 
2.5 
4.5 
6 
8.5 
Total WBC (x 109/L)  Normal ≤8.5 
High 8.6-11 
Very High >11 
0 
0.5 
1.5 
Lymphocyte Percentage Normal 20-40% 
Low 12-19.9% 
Very low <12% 
0 
1 
2.5 
Risk Group 30 day survival Total Score PaP 
A 
B 
C 
>70% 
30-70% 
<30% 
0-5.5 
5.6-11 
11.1-17.2 
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Table 5: The D-PaP 
Criterion for D-PaP  Score 
Dyspnoea Yes 
No 
1 
0 
Anorexia Yes 
No 
1.5 
0 
KPS ≥30 
10-20 
0 
2.5 
CPS (weeks) >12 
11-12 
7-10 
5-6 
3-4 
1-2 
0 
2 
2.5 
4.5 
6 
8.5 
Total WBC (x 109/L)  Normal ≤8.5 
High 8.6-11 
Very High >11 
0 
0.5 
1.5 
Lymphocyte Percentage Normal 20-40% 
Low 12-19.9% 
Very low <12% 
0 
1 
2.5 
Delirium Yes 
No 
2 
0 
Risk Group 30 day survival Total Score D-PaP 
A 
B 
C 
>70% 
30-70% 
<30% 
0-7 
7.1-12.5 
12.6-19.5 
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Table 6: The BCI 
Total BCI score = multiply serum vitamin B12 level (pmol/l) by serum CRP level (mg/l) 
Risk Group BCI Score 
1 
2 
3 
≤ 10000 
10001-40000 
>40000 
 
Table 7: The PiPS (A and B) 
PiPS A PiPS B Score 
Breast cancer 
Male Genital Organs 
Distant metastases 
Liver metastases 
Bone metastases 
Mental test score (0-10) 
Pulse (bpm) 
Anorexia 
Dyspnoea 
Dysphagia 
Loss of weight in previous month 
ECOG (0-4) 
Global Health (1-7) 
Male Genital Organs 
Distant metastases 
Bone metastases 
Mental test score (0-10) 
Pulse (bpm) 
Anorexia 
Fatigue 
ECOG (0-4) 
Global Health (1-7) 
WBC 
Neutrophils 
Lymphocytes 
Platelets 
Urea 
ALT 
Alk Phos 
Albumin 
CRP 
The presence/absence 
of the indices is entered 
into electronic tool 
which calculates 
survival 
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Table 8: The PPI 
Criterion  Score 
Palliative Performance Scale 10-20 
30-50 
≥60 
4 
2.5 
0 
Oral Intake Severely reduced 
Moderately reduced 
normal 
2.5 
1 
0 
Oedema Present 
absent 
1 
0 
Dyspnoea at rest Present  
absent 
3.5 
0 
Delirium Present 
absent 
4 
0 
Risk Group Survival PPI score 
A 
B 
C 
Longer than 6 weeks 
Shorter than 6 weeks 
Shorter than 3 weeks 
≤4 
>4 
>6 
 
Table 9: The PPS 
PPS Range Level of Function/condition 
 100% → 0% Normal → Death 
 
 
Table 10: The GPS/mGPS 
 CRP Alb Score 
GPS CRP ≥ 10 mg/L 
CRP > 10 mg/L 
Normal CRP 
CRP > 10 mg/L 
Albumin ≥ 35 g/L  
Normal albumin  
Albumin < 35 g/L  
Albumin < 35 g/L 
0 
1 
1 
2 
mGPS CRP ≤ 10 mg/L 
CRP > 10 mg/L 
CRP > 10 mg/L 
albumin ≥ 35 g/L  
Normal albumin  
Albumin < 35 g/L 
0 
1 
2 
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Appendix 3 
PaP (Palliative Prognostic Score)and D-PaP (Delirium PaP) (Tables 4 and 5) 
The PaP score was constructed by the Italian Multicentre and Study Group in Palliative Care 
and validated in patients with advanced incurable cancer using thirty day survival probability.  
The D-PaP (Delirium-PaP) is a modified version of the PaP, incorporating a delirium 
assessment which slightly improved the predictive accuracy of the PaP. The PaP and D-PaP 
are the only prognostic tools included in this review which use clinician predicted survival 
(CPS) as one of their indices. The PaP has six parameters; four subjective (clinical) and two 
objective (biomarkers). The PaP and D-PaP both rely heavily on Clinician Predicted Survival, 
a subjective parameter which can add an extra 8.5 points to the total score (PaP maximum 
17.5; D-PaP maximum 19.5). The other parameters (biomarkers and symptoms) contribute a 
a maximum of 2.5 points making this tool heavily reliant on the clinician’s expertise in 
prognostication.   
 
A key component of the  PaP is  clinician predicted survival (CPS). It has been argued that 
CPS is dependent on physicians having sufficient knowledge and experience to make assess 
this adequately.  From the eligible studies it was noted that oncologists’ (i.e. non palliative 
care specialists) CPS was shown to be well calibrated but individual predictions imprecise. 
Using the CPS from non-specialists still enabled the PaP to predict the short term survival (30 
days) of patients with advanced cancer ‘reasonably well’. The inclusion of CPS, therefore, 
does not detract from the PaP score being a unique combination of physician’s judgement, 
corrected and integrated with a series of other objective parameters, optimising the score. In 
spite of this, this tool is not used routinely. This may be due to its heavy reliance on CPS and 
therefore clinicians do not need to use a tool which weights their existing opinion heavily, 
and therefore they could argue will not alter their survival estimate.  The other components of 
the tool have been individually validated for their accuracy in estimating prognosis, however 
the individual weighting of each parameter is not known since no study has compared every 
clinical and biomarker important in prognosis in advanced cancer.   
 
 
BCI (B12/CRP Index) (Table6) 
The BCI was developed by a group at the University of London, UK, following the EAPC’s 
recommendations in 2005. It was initially validated in patients with advanced incurable 
cancer admitted to an elderly care facility. It can estimate up to 90 day mortality. Of interest 
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is that the BCI incorporates vitamin B12 levels as a marker of prognosis; the rationale for this 
is that  increased levels are present in myeloproliferative disorders, hepatocellular carcinoma 
and metastatic liver disease. It consists of two objective (biomarker) parameters, CRP and 
B12.  However, vitamin B12 is not always analysed routinely in patients and may explain the 
lack of further research into this tool.  
 
PiPS (Prognosis in Palliative Care Study) (Table 7) 
The PiPS was developed in a UK population with locally advanced or metastatic cancer. 
There are two versions of the tool (PiPS A and PiPS B) and differ in that PiPS B incorporates 
biomarkers when assessing survival. It predicts survival up to and greater than 55 days. The 
PiPS A has 13 subjective parameters whereas the  PiPS B has nine subjective and eight 
objective (biomarker) parameters. The PiPS, similar to other tools, relies on subjective 
parameters however in this case, they are orientated towards specific symptoms, signs and 
disease burden and many are suggested by the EAPC as individual prognostic factors. The 
relative weighting of each of the prognostic factors is not available in the public domain, 
instead the tool is accessed electronically and a score issued.  
 
PPI (Palliative Prognostic Index) (Table 8) 
The PPI was developed in Japan in 1999, in patients with advanced incurable cancer. It 
divides survival into three groups and estimates survival up to 6 weeks. Risk group A (PPI 
score ≤4) has an estimated survival of more than six weeks. Risk group B (PPI score 5) has 
an estimated survival of less than six weeks but greater than three weeks. Risk group C (PPI 
score >6) has an estimated survival of less than three weeks.   It consists of nine subjective 
parameters (the Palliative Performance Scale, oral intake, oedema, dyspnoea at rest and 
delirium) and reports the presence or absence of signs and symptoms with similar weighting 
given to the different parameters. One of the parameters used is the Palliative Performance 
Scale (PPS) that is a prognostic tool in its own right. By incorporating the PPS into the PPI, 
more subjective parameters are incorporated and whilst this may increase the prognostic 
accuracy, it may increases bias and the complexity and reduce clinical utility.   
 
 
PPS (Palliative Performance Scale) (Table 9) 
The PPS was validated in a palliative care population in Canada. It provides a percentage 
score based upon subjective indices giving a survival estimate up to 3 months. Survival 
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accuracy of intermediate scores has been noted to be variable. It consists of six subjective 
parameters. Many of these parameters are focussed on aspects of performance status 
including ambulation, activity levels and performance status itself. Performance status is the 
gold standard in assessing a patient’s fitness, therefore this tool is bias towards performance 
status in that synonyms of performance status are included as parameters (e.g. levels of 
ambulation, activity and self-care). One of the other parameters is conscious level, which 
could have been objectified by incorporating the Glasgow Coma Scale.  
 
In conclusion the PPS has been extensively studied in a large patient population with 
advanced cancer, including multiple cancer types. It has performed well in the majority of the 
studies looking at the tool individually, the only criticism being its better accuracy with lower 
PPS scores. It has also been compared several times with other prognostic tools with varying 
results and again demonstrates comparable accuracy to other tools with lower PPS scores. 
The components of this tool are heavily bias towards performance status and disease burden 
emphasising the importance of these clinical markers in prognosis.  
 
GPS (the Glasgow Prognostic Score) (Table 10) 
The GPS was originally developed in patients with non-small cell lung cancer and 
subsequently refined to the mGPS The GPS combines CRP and albumin to give a score of 0, 
1 or 2, with increasing score suggesting decreased survival: CRP<10=0; CRP>10=1 (albumin 
>35); and  CRP>10 + Albumin<35 =2 It has been validated in individual cancer types in 
addition to large populations of patients with advanced incurable cancer. 23 The GPS is  
entirely objective as the information needed to calculate   the score is based on biomarker 
results. The GPS has been developed since the EAPC’s recommendations in 2005 and meets 
the requirements set that any prognostic tool   is quick and easy to use, and its scoring system 
is very simple. The GPS is also able to predict survival accurately several months prior to 
death. It fulfils the EAPC’s recommendations of being quick and easy to use, along with 
robust evidence of its accuracy.  
 
 
 
